Key Highlights
- BioRestorative Therapies shares closed down 29% at $0.14.
- The company is set to execute a 1-for-20 Reverse Stock Split on September 7, 2026.
- Trading on a post-split basis is set to begin September 8.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares closed down 29% at $0.14 as the company is set to execute a 1-for-20 reverse stock split on September 7, 2026.
What Happened
Trading on a post-split basis is scheduled to begin September 8, 2026.
Market Reaction
Shares fell sharply ahead of the scheduled reverse split, a pattern often seen as traders exit positions ahead of a purely mechanical adjustment to a stock's share count and price.
Outlook
The transition to post-split trading beginning September 8 represents the next relevant development for BioRestorative Therapies shareholders.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.